Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax and CM336 in Newly Diagnosed Systemic AL Amyloidosis
NCT07687004Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of sonrotoclax, gamgertamig in amyloid light chain amyloidosis, sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sonrotoclaxgamgertamig
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT07687004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07687004.